Kemoterapiye Bağlı Alopesi Sıklığı ve Hastaların Baş etme Yöntemleri

Yıl 2022, Cilt: 17 Sayı: 1, 77 - 83, 21.03.2022

Nurcan Kolaç , Seçil Taylan

https://doi.org/10.17517/ksutfd.837378

Öz

Purpose: The aim of the study is to determine the prevalence of chemotherapy-induced alopecia and the patients’ coping methods with alopecia.

Materials and Methods: This descriptive study was conducted with 240 patients who applied to chemotherapy unit of two private hospitals in Istanbul between December 2019 and January 2020. The data were collected using a patient information form developed by the researchers upon the literature review.
Results: It was determined that 85.7% of the women experienced alopecia problem and the difference was significant according to their gender (p=0.00). 92.0% of patients with genitourinary system cancer and 88.5% of breast cancer patients experienced alopecia, the difference was statistically significant, and the significance was caused by experiencing alopecia more in these cancer types than the other cancer types (p=0.007). It was determined that 82.5% of the patients, who were receiving chemotherapy for less than a year, statistically significantly experienced alopecia more compared to the patients who were receiving chemotherapy for a longer period (p=0.031). It was also found that 69.7% of patients with Stage IV cancer experienced alopecia but they experienced alopecia statistically significantly less compared to the other stage patients (p=0.040). When the patients were examined in terms of diagnosis time according to family history of breast cancer, it was determined that 43.6% of those, who had family history of breast cancer, and 63.8% of those, who had no family history of breast cancer, were diagnosed in the stage II of their disease. The distribution of the cancer diagnosis time of patients according to having breast cancer history in the family was statistically significant (p=0.000). It was determined that 28.2% of the patients who had family history of breast cancer and 21.0% of the patients, who had no family history of breast cancer, noticed the lump for the first time in their regular self-breast examination. The distribution of duration of cancer diagnosis based on family history of breast cancer and the way of noticing the lump in the breast were statistically significant (p=0.000, p=0.014). It was also determined that 61.0% of the patients experiencing alopecia used a wig-bonnet (p=0.00) and there was no statistically significant difference between experiencing alopecia and age, marital status, occupation, place of residence, income status and social security.
Conclusion: Alopecia was seen to be more common in women. Patients with genito-urinary system and breast cancer experienced alopecia more than other cancer patients. More than half of the women used bonnets and wigs. As the education level increased, women’s status of using bonnet and wig increased as well.

Anahtar Kelimeler

chemotherapy, cancer, gender

Destekleyen Kurum

Araştırmayı destekleyen kurum yoktur.

Proje Numarası

Proje değildir

Teşekkür

Araştırmaya katılan tüm hastalara ve araştırmanın yapılmasına izin veren kurumlara teşekkür ederiz.

Determination of the Factors Affecting the Frequency and of Chemotherapy- Induced Alopecia and Methods of Coping with Alopecia

Öz

Purpose: The aim of the study is to determine the prevalence of chemotherapy-induced alopecia and the patients’ coping methods with alopecia.

Materials and Methods: This descriptive study was conducted with 240 patients who applied to chemotherapy unit of two private hospitals in Istanbul between December 2019 and January 2020. The data were collected using a patient information form developed by the researchers upon the literature review.
Results: It was determined that 85.7% of the women experienced alopecia problem and the difference was significant according to their gender (p=0.00). 92.0% of patients with genitourinary system cancer and 88.5% of breast cancer patients experienced alopecia, the difference was statistically significant, and the significance was caused by experiencing alopecia more in these cancer types than the other cancer types (p=0.007). It was determined that 82.5% of the patients, who were receiving chemotherapy for less than a year, statistically significantly experienced alopecia more compared to the patients who were receiving chemotherapy for a longer period (p=0.031). It was also found that 69.7% of patients with Stage IV cancer experienced alopecia but they experienced alopecia statistically significantly less compared to the other stage patients (p=0.040). When the patients were examined in terms of diagnosis time according to family history of breast cancer, it was determined that 43.6% of those, who had family history of breast cancer, and 63.8% of those, who had no family history of breast cancer, were diagnosed in the stage II of their disease. The distribution of the cancer diagnosis time of patients according to having breast cancer history in the family was statistically significant (p=0.000). It was determined that 28.2% of the patients who had family history of breast cancer and 21.0% of the patients, who had no family history of breast cancer, noticed the lump for the first time in their regular self-breast examination. The distribution of duration of cancer diagnosis based on family history of breast cancer and the way of noticing the lump in the breast were statistically significant (p=0.000, p=0.014). It was also determined that 61.0% of the patients experiencing alopecia used a wig-bonnet (p=0.00) and there was no statistically significant difference between experiencing alopecia and age, marital status, occupation, place of residence, income status and social security.
Conclusion: Alopecia was seen to be more common in women. Patients with genito-urinary system and breast cancer experienced alopecia more than other cancer patients. More than half of the women used bonnets and wigs. As the education level increased, women’s status of using bonnet and wig increased as well.

Anahtar Kelimeler

chemotherapy, alopecia, canser

Proje Numarası

Proje değildir

Kaynakça

• 1. Bahçetepe N, Kutlubay Z, Engin B, Tüzün Y. Cutaneous Effects Of Chemotherapeutic Agen. Dermatoz .2019 ;4: 69-76.
• 2. Türkiye Kanser İstatistikleri. (2014). Electronic Resources [Online]. Available From: Https://Hsgm.Saglik.Gov.Tr/Tr/Kanser-İstatistikleri/Yillar/495-2014-Y%C4%B1l%C4%B1-T%C3%Bcrkiye-Kanser-İstatistikleri.Html. Sayfa 44- Satır 1-10 (Erişim 15 Ocak 2020)
• 3. Baykara O. Current Modalıtıes In Treatment Of Cancer. Balıkesır Health Scıences Journal.2016; 5:154-165.
• 4. Bichsel KJ, Gogia N, Malouff T, Et Al. Role For The Epidermal Growth Factor Receptor İn Chemotherapy-İnduced Alopecia. Plos One.2013; 8: 7e69368.
• 5. Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, Lee SE. Impact Of Chemotherapy-İnduced Alopecia Distress On Body İmage, Psychosocial Well-Being, And Depression İn Breast Cancer Patients. Psycho-Oncology. 2014;23: 1103–1110.
• 6. Gupta S, Khatoon R, Hair Loss-An Analys And Updated Treatment. Journal Of Dental And Medical Sciences.2015; 14:77-812.
• 7. Aygın D, Eti Aslan F. A Study Of Sexual Dysfunctıon In Women Wıth Breast Cancer. The Journal Of Breast Health 2008; 4:105-114.
• 8. Batchelor D. Hair And Cancer Chemotherapy: Consequences And Nursing Care A Literature Study. European Journal Of Cancer Care 2001;10: 147-163. 8.
• 9. Breed W, Van Den Hurk C, Peerbooms M. Presentation, İmpact And Prevention Of Chemotherapy-İnduced Hair Loss: Scalp Cooling Potentials And Limitations. Expert Rev Dermatol.2011; 6:109.
• 10. Karabulutlu Ö. Kemoterapi Alan Hastalarda Semptom Yönetimi ve Yaşam Kalitesinin Sürdürülmesi. İstanbul Universty Florence Nightingale Journal Of Nursing 2009;17: 218-225.
• 11. Komen MM, Smorenburg CH, Van Den Hurk CJ, Nortier JW. Factors İnfluencing The Effectiveness Of Scalp Cooling İn The Prevention Of Chemotherapy-İnduced Alopecia. Oncologist.2013; 18:885.
• 12. Chon SY, Champion RW. Geddes ER. Rashid RM. Chemotherapy-İnduced Alopecia. J Am Acad Dermatol.2012; 67: E37. 13. Can G. Side Effects Of Antineoplastic Drugs And Nursing Approaches. Journal Of Education And Research In Nursing.2005; 2:8-15.
• 14. Ateş AS, Olgun N. Perceptions And Attitudes Of Nurses Towards Chemotherapy Induced Alopeciajournal Of Academic Reserach İn Nursing.2015; 1:15.
• 15. Carelle N, Piotto E, Bellanger A, Germanaud PDJ. Thuillier A. Khayat MD. Changing Patient Perceptions Of The Side Effects Of Cancer Chemotherapy. Cancer .2005;95 155-163.
• 16. Mcgarvey EL , Baum LD , Pinkerton RC , Rogers LM: Psychological Sequelae And Alopeciaamaong Women 2001;9:283-9. 17. Dueland S. Sauer T. Lund-Johansen F, Et Al. Epidermal Growth Factor Receptor İnhibition İnduces Trichomegaly. Acta Oncol.2003; 42:345.
• 18. Fonia A, Cota C. Setterfield JF, Et Al. Permanent Alopecia İn Patients With Breast Cancer After Taxane Chemotherapy And Adjuvant Hormonal Therapy: Clinicopathologic Findings İn A Cohort Of 10 Patients. J Am Acad Dermatol.2017; 76:948.
• 19. Hunt N, Mchale S. The Psychological İmpact Of Alopecia. BMJ (Clinical Research Ed.), 2005; 331(7522), 951–953.
• 20. Shin H, Jo SJ, Kim DH, Et Al. Efficacy Of İnterventions For Prevention Of Chemotherapy-İnduced Alopecia: A Systematic Review And Meta-Analysis. Int J Cancer.2015; 136: E 442.
• 21. Saraswat N, Chopra A. Sood A K.Amboj P, Kumar S. Descriptive Study To Analyze Chemotherapy-Induced Hair Loss And İts Psychosocial Impact İn Adults: Our Experience From A Tertiary Care Hospital. İndian Dermatol Online J.2015; 10: 426-430.
• 22. Hindistan S, Çilingir D, Nural N, Akkaş Gürsoy A. Applıcatıons Of Patıents Wıth Hematologıc Cancers For Experıenced Symptoms Due To Chemotherapy. Gümüşhane University Health Scıences Journal 2012; 153-164.
• 23. Botchkarev VA, Komarova EA, Siebenhaar F, Et Al. P53 İs Essential For Chemotherapy-İnduced Hair Loss. Cancer Res.2000; 60:5002.
• 24. Glaser DA,Hossain P, Perkins W, Et Al. Long-Term Safety And Efficacy Of Bimatoprost Solution 0·03% Application To The Eyelid Margin For The Treatment Of İdiopathic And Chemotherapy-İnduced Eyelash Hypotrichosis: A Randomized Controlled Trial. Br J Dermatol.2015; 172:1384.